ImaginAb, a clinical stage biotech company in Inglewood, has raised $21 Million in Series B financing.

Investment partners include Mérieux Développement, Novartis Venture Funds, Cycad Group and Nextech Invest, according to a company statement on Thursday.

ImaginAb harnesses antibody technology to detect diseases in living organisms.

“We have made excellent progress with our programs in cancer and immunology,” said Dr. Christian Behrenbruch, co-founder and Chief Executive of of ImaginAb. “We are pleased to have concluded this round of growth capital to accelerate the development of our lead program in prostate cancer, and continue to expand our product pipeline.”